Laura Testa

Sao Paulo, SP, Brazil

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 59 publications

Attenuated pressor and sympathetic neural responses to exercise in long-term breast cancer survivors: role of the muscle metaboreflex.

Attenuated pressor and sympathetic neural responses to exercise in long-term breast cancer survivors: role of the muscle metaboreflex.

Journal: American journal of physiology. Heart and circulatory physiology

Published: May 06, 2026

Sympathetic Neural Overactivation, Vascular Dysfunction, and Exercise Intolerance in Long-Term Survivors of Breast Cancer Treated With Doxorubicin and Trastuzumab-Based Chemotherapy.

Sympathetic Neural Overactivation, Vascular Dysfunction, and Exercise Intolerance in Long-Term Survivors of Breast Cancer Treated With Doxorubicin and Trastuzumab-Based Chemotherapy.

Journal: Journal of the American Heart Association

Published: March 13, 2026

Clinical Impact and Clinicopathologic Correlations of Oncotype DX in Hormone Receptor-Positive/HER2-Negative Early Breast Cancer: Real-World Evidence From a Large Brazilian Cohort (GBECAM 0520).

Clinical Impact and Clinicopathologic Correlations of Oncotype DX in Hormone Receptor-Positive/HER2-Negative Early Breast Cancer: Real-World Evidence From a Large Brazilian Cohort (GBECAM 0520).

Journal: JCO oncology practice

Published: March 06, 2026

Neoadjuvant pembrolizumab plus chemotherapy in germline BRCA-mutated early triple-negative breast cancer: a multicenter real-world cohort.

Neoadjuvant pembrolizumab plus chemotherapy in germline BRCA-mutated early triple-negative breast cancer: a multicenter real-world cohort.

Journal: NPJ breast cancer

Published: February 20, 2026

Long-term outcomes in triple-negative breast cancer after a pathologic complete response: does the type of neoadjuvant therapy matter?

Long-term outcomes in triple-negative breast cancer after a pathologic complete response: does the type of neoadjuvant therapy matter?

Journal: Breast cancer research and treatment

Published: January 03, 2026

Treatment patterns and safety of adjuvant therapy after chemoimmunotherapy for early-stage triple-negative breast cancer: real-world data from the Neo-Real/GBECAM 0123 study.

Treatment patterns and safety of adjuvant therapy after chemoimmunotherapy for early-stage triple-negative breast cancer: real-world data from the Neo-Real/GBECAM 0123 study.

Journal: Breast cancer research and treatment

Published: November 22, 2025

Neoadjuvant pembrolizumab plus chemotherapy in older patients with early-stage triple-negative breast cancer: real-world insights from neo-real/GBECAM-0123.

Neoadjuvant pembrolizumab plus chemotherapy in older patients with early-stage triple-negative breast cancer: real-world insights from neo-real/GBECAM-0123.

Journal: NPJ breast cancer

Published: November 02, 2025

Reply letter: Pathologic complete response in TNBC: A shield against recurrence, but not the brain?

Reply letter: Pathologic complete response in TNBC: A shield against recurrence, but not the brain?

Journal: Breast (Edinburgh, Scotland)

Published: September 18, 2025

Overall survival with abemaciclib in early breast cancer.

Overall survival with abemaciclib in early breast cancer.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: September 05, 2025

DESTINY-Breast08: A Phase Ib Study of Trastuzumab Deruxtecan in Combination with Other Anticancer Therapies in Patients with HER2-Low Metastatic Breast Cancer.

DESTINY-Breast08: A Phase Ib Study of Trastuzumab Deruxtecan in Combination with Other Anticancer Therapies in Patients with HER2-Low Metastatic Breast Cancer.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: June 12, 2025

Cancer outcomes in patients eligible for adjuvant cyclin-dependent kinase 4 and 6 inhibitors but spared adjuvant chemotherapy by Oncotype Dx: A multicenter retrospective GBECAM 0520 study.

Cancer outcomes in patients eligible for adjuvant cyclin-dependent kinase 4 and 6 inhibitors but spared adjuvant chemotherapy by Oncotype Dx: A multicenter retrospective GBECAM 0520 study.

Journal: Breast (Edinburgh, Scotland)

Published: May 04, 2025

Central nervous system relapse in triple-negative breast cancer patients achieving pathological complete response after neoadjuvant chemotherapy: A retrospective cohort analysis.

Central nervous system relapse in triple-negative breast cancer patients achieving pathological complete response after neoadjuvant chemotherapy: A retrospective cohort analysis.

Journal: Breast (Edinburgh, Scotland)

Published: May 03, 2025

Showing 1-12 of 59

Last Updated: 09/26/2026